This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $443,544.00 to Dasisimulations LLC to develop and validate an innovative, AI-driven software platform for automating complex pre-procedural measurements required for transcatheter aortic valve replacement (TAVR) procedures. The software aims to reduce the manual, time-intensive nature of current measurement processes and improve the efficiency and consistency of TAVR planning. The project has two key objectives: (1) develop and validate the measurement module to extract TAVR procedural measurements, and (2) prepare and submit the FDA 510(k) clearance documentation. This award, with a performance period from August 1, 2024 to July 31, 2025, represents an important step in bringing this disruptive, AI-based technology to the cardiovascular care setting.
Generated 1/28/25, 8:14 AM